AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX 15,270
+110 (0.73%)
Feb 17, 2026, 11:14 AM GMT
AstraZeneca Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
| 58,739 | 54,073 | 45,811 | 44,351 | 37,417 | |
Revenue Growth (YoY) | 8.63% | 18.04% | 3.29% | 18.53% | 40.58% |
Cost of Revenue | 10,771 | 9,638 | 8,040 | 8,641 | 12,005 |
Gross Profit | 47,968 | 44,435 | 37,771 | 35,710 | 25,412 |
Selling, General & Admin | 20,303 | 19,453 | 18,025 | 17,460 | 14,673 |
Research & Development | 14,061 | 12,243 | 10,373 | 9,669 | 8,049 |
Other Operating Expenses | -376 | -190 | -275 | -231 | -207 |
Operating Expenses | 33,988 | 31,506 | 28,123 | 26,898 | 22,515 |
Operating Income | 13,980 | 12,929 | 9,648 | 8,812 | 2,897 |
Interest Expense | -1,694 | -1,403 | -1,219 | -917 | -776 |
Interest & Investment Income | 360 | 345 | 301 | 81 | 43 |
Earnings From Equity Investments | -7 | -28 | -12 | -5 | -64 |
Currency Exchange Gain (Loss) | - | -42 | -34 | -16 | -20 |
Other Non Operating Income (Expenses) | - | -134 | -292 | -370 | -478 |
EBT Excluding Unusual Items | 12,639 | 11,667 | 8,392 | 7,585 | 1,602 |
Merger & Restructuring Charges | -237 | -1,154 | -604 | -4,201 | -1,283 |
Gain (Loss) on Sale of Investments | - | - | - | - | 776 |
Gain (Loss) on Sale of Assets | - | 60 | 292 | 216 | 509 |
Asset Writedown | - | -1,574 | -434 | -241 | -2,069 |
Legal Settlements | - | -48 | -1,013 | -789 | -48 |
Other Unusual Items | - | -260 | 266 | -69 | 248 |
Pretax Income | 12,402 | 8,691 | 6,899 | 2,501 | -265 |
Income Tax Expense | 2,169 | 1,650 | 938 | -792 | -380 |
Earnings From Continuing Operations | 10,233 | 7,041 | 5,961 | 3,293 | 115 |
Minority Interest in Earnings | -8 | -6 | -6 | -5 | -3 |
Net Income | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
Net Income to Common | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
Net Income Growth | 45.34% | 18.14% | 81.11% | 2835.71% | -96.50% |
Shares Outstanding (Basic) | 1,550 | 1,550 | 1,549 | 1,548 | 1,418 |
Shares Outstanding (Diluted) | 1,562 | 1,563 | 1,562 | 1,560 | 1,427 |
Shares Change (YoY) | -0.06% | 0.06% | 0.13% | 9.32% | 8.68% |
EPS (Basic) | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 |
EPS (Diluted) | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 |
EPS Growth | 45.33% | 18.11% | 80.57% | 2571.43% | -96.76% |
Free Cash Flow | 11,765 | 9,937 | 8,984 | 8,717 | 4,872 |
Free Cash Flow Per Share | 7.53 | 6.36 | 5.75 | 5.59 | 3.41 |
Dividend Per Share | 3.200 | 3.100 | 2.900 | 2.900 | 2.870 |
Dividend Growth | 3.23% | 6.90% | - | 1.04% | 2.50% |
Gross Margin | 81.66% | 82.18% | 82.45% | 80.52% | 67.92% |
Operating Margin | 23.80% | 23.91% | 21.06% | 19.87% | 7.74% |
Profit Margin | 17.41% | 13.01% | 13.00% | 7.41% | 0.30% |
Free Cash Flow Margin | 20.03% | 18.38% | 19.61% | 19.66% | 13.02% |
EBITDA | 19,705 | 17,567 | 14,224 | 13,744 | 6,701 |
EBITDA Margin | 33.55% | 32.49% | 31.05% | 30.99% | 17.91% |
D&A For EBITDA | 5,725 | 4,638 | 4,576 | 4,932 | 3,804 |
EBIT | 13,980 | 12,929 | 9,648 | 8,812 | 2,897 |
EBIT Margin | 23.80% | 23.91% | 21.06% | 19.87% | 7.74% |
Effective Tax Rate | 17.49% | 18.98% | 13.60% | - | - |
Revenue as Reported | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.